Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > REGULATORY
REGULATORY
- LDP Junior Politicians Set Up Vaccine Study Group
May 31, 2019
- “Drugs for Specific Use” Might Include NTD Medicines: MHLW Official
May 30, 2019
- Chuikyo Subcommittee Agrees on Discussion Timeline, Topics for 2020 Drug Pricing Reform
May 30, 2019
- MHLW Panel OKs Public Knowledge-Based Applications for Add’l Indication for Rituxan
May 30, 2019
- Japan Approves Health Coverage for Cancer Gene Panel Tests
May 30, 2019
- Alnylam’s RNAi Drug Now in Line for Japan Approval in June
May 29, 2019
- Japan’s 2nd Enbrel Biosimilar, Pfizer’s Herceptin Follow-On Get Listing
May 28, 2019
- Quizartinib Added to List of MHLW Panel Review on May 30
May 24, 2019
- LDP’s Life Science Study Group Eyes Enhancement of Databases, AMED Functions
May 23, 2019
- MHLW Approves Entyvio’s Crohn’s Disease Indication and More
May 23, 2019
- JPMA Prods Revamp of PMP, Launch Premiums, Comparator Selection Criteria towards 2020 Reform
May 22, 2019
- Minister Says Kymriah Pricing Appropriate Even with Low Cost Disclosure Ratio
May 22, 2019
- MHLW Planning to Launch Report System on Inappropriate Detailing Activity as Early as Summer
May 21, 2019
- Govt, Industry Share Views on Challenges in Data Use, Drug Pricing
May 21, 2019
- 74 Suspected Violations Found in Sales Reps’ Advertising Activities: MHLW
May 21, 2019
- Eli Lilly Ordered to Issue Blue Letter on Verzenio
May 20, 2019
- Kymriah’s Impact on Health Insurance Finances Limited for Now: Health Minister
May 20, 2019
- LDP Lawmaker Group Discusses Measures for APIs to Ensure Stable Generic Drug Supplies
May 17, 2019
- Chugai’s Entrectinib Up for Review for NTRK Tumors on May 30; Label Expansions for Lynparza, Cyramza Also on Agenda
May 17, 2019
- MHLW Compiles Optimal Promotion Guidelines for Kymriah
May 16, 2019
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…